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Glutathione S-transferaseAbstract Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a
wide variety of cancers with varying degrees of success. In particular, cisplatin has been used to treat
late stage non-small cell lung cancer (NSCLC) as the standard of care. However, therapeutic
outcomes vary from patient to patient. Considerable efforts have been invested to identify biomark-
ers that can be used to predict cisplatin sensitivity in NSCLC. Here we reviewed current evidence for
cisplatin sensitivity biomarkers in NSCLC. We focused on several key pathways, including
nucleotide excision repair, drug transport and metabolism. Both expression and germline DNA
variation were evaluated in these key pathways. Current evidence suggests that cisplatin-based
treatment could be improved by the use of these biomarkers.Introduction
Lung and bronchus cancer is the leading cause of cancer mor-
tality worldwide, responsible for 1.59 million deaths in 2012
[1]. It is also the leading cause of cancer deaths in the US with
a predicted 159,260 deaths in 2014 [2]. About 85% of all lung
cancers are non-small cell lung cancer (NSCLC), whereas the
remaining 15% are small cell lung cancer [3]. The standard
of care for advanced (stages III and IV) NSCLC is cisplatin
in combination with 1–3 of the following drugs including
paclitaxel, gemcitabine, docetaxel, vinorelbine, irinotecan andpemetrexed, and concurrent radiotherapy for stage IIIB
NSCLC patients [4]. Despite efforts to improve efﬁcacy of
therapy, the 5-year survival rate for NSCLC over all stages
is still only 17% [5]. While many patients initially respond to
cisplatin-based chemotherapy, others show intrinsic or
acquired non-response [3]. Considerable efforts have been
dedicated to the study of biomarkers for cisplatin sensitivity
in NSCLC in order to improve therapeutic efﬁcacy. In this
review we will focus on three key pathways that are known
to be associated with the effect of cisplatin on NSCLC. These
three pathways/classes of enzymes are: nucleotide excision
repair (NER), which represents drug targets; copper transport-
ers, which play a role in drug uptake; and glutathione S-trans-
ferases (GSTs), which play a role in drug metabolism. For each
of these pathways we reviewed current evidence for the use of
mRNA expression and protein expression levels as biomarkers
for cisplatin sensitivity. In addition, we discussed singlences and
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dence for their involvement in cisplatin sensitivity in NSCLC.
General mechanism of action for cisplatin
Cisplatin is thought to enter the cell through a combination of
passive uptake and active transport such as through the copper
transporters [6]. Once in the cell, cisplatin becomes aquated
and positively charged. It is then able to interact with and
intercalate tumor DNA, forming cross-links and unwinding
the helix; such DNA damage results in inhibition of DNA rep-
lication, eventually triggering apoptosis and necrosis (Figure 1)
[7,8]. Platinating agents can form four types of links on DNA,
i.e., monoadducts (which typically become intrastrand cross-
links), intrastrand crosslinks, interstrand crosslinks and
DNA-protein crosslinks [8]. In addition to DNA, cisplatin is
able to react with thiol-containing compounds such as gluta-
thione [8]. By forming glutathione adducts, cisplatin is detoxi-
ﬁed, which reduces efﬁcacy. After forming adducts with DNA,
the cisplatin molecules activate the endoplasmic reticulum
(ER) stress pathway (also known as the unfolded protein
response), thereby activating apoptotic caspases [8]. Sensitivity
to cisplatin is known to be mediated by multiple different
mechanisms likely working synergistically to prevent, detect
and remove DNA adducts formed by cisplatin. In this review
we focused on NER, copper transport and GSTs as proxies for
drug action, uptake and metabolism, respectively (Figure 1).
Our goal is to present a broad picture of cisplatin’s mechanism
of action while simultaneously examining each of these path-
ways in detail for their role in cisplatin sensitivity.
NER and cisplatin sensitivity
Over 90% of DNA adducts formed by cisplatin are 1,2-intra-
strand d(GpG) [9] or 1,2-intrastrand d(ApG) crosslinks [9,10].Figure 1 Schematic diagram of cisplatin’s mechanism of action
The three representative pathways discussed in the text are
illustrated, including drug action, uptake and metabolism. ATP7A
and ATP7B, ATPase, copper transporting, alpha polypeptides A
and B; CTR1 and CTR2, copper transporters 1 and 2; ERCC1,
excision repair cross-complementation group 1; GSTM1 and P1,
glutathione S-transferases Mu 1 and pi 1; XPA, XPD and XDF,
xeroderma pigmentosum complementation groups A, D and F.Such adducts, in addition to other less common crosslinks, are
known to be detected and excised by NER [11]. Further,
strong evidence for signiﬁcant pharmacogenomic associations
exists for genes involved in the NER pathway, indicating
treatment could be improved by clinical assessments of the
genes in the NER pathway.
NER mechanism of action
The exact mechanism of action underlying the role of NER in
sensitivity to cisplatin has been discussed at length elsewhere
[12,13] and is not reviewed in detail in the present article. In brief,
NER is responsible for the detection and removal of bulkyDNA
adducts by means of ssDNA excision. There exist two distinct
modes for the detection of DNA damage within NER––global
genomic NER (GG-NER) and transcription coupled NER
(TC-NER). These two modes are identical in essence except
for damage detection. While GG-NER requires the use of xero-
derma pigmentosum complementation group C (XPC) and
deafness/dystonia proteins (DDP) to actively detect damage,
TC-NER is passively activated when RNA polymerase stalls
at the damage site. Furuta and colleagues found that cisplatin
sensitivity is mediated through TC-NER exclusively [14], while
Rosell et al. reported that there is evidence for both modes of
NER modulating cisplatin resistance [15]. After damage detec-
tion, excision repair cross-complementation group 1 (ERCC1)
forms a complex with xeroderma pigmentosum complementa-
tion group F (XPF) and creates an incision 23 nucleotides
upstream from the DNA adduct. Cell lines defective in ERCC1
or XPF are approximately 40 times more sensitive to cisplatin
[16], indicating that this step is critical in cisplatin sensitivity.
ERCC1 and cisplatin sensitivity in NSCLC
ERCC1 is the rate-limiting protein in the NER pathway and
has therefore been a subject of many studies attempting to
explain cisplatin resistance. The ﬁrst report on ERCC1’s role
in cisplatin resistance came from Dabholkar and colleagues
in cells harvested from ovarian cancer tissue. Tissues from
patients whose tumors showed clinical resistance to cisplatin
exhibited signiﬁcantly higher levels of ERCC1 mRNA
(P= 0.026) [17]. Since then, there have been a variety of
reports indicating that ERCC1 mRNA and protein expression
levels in tumors are indicative of cisplatin sensitivity in
NSCLC. Some researchers have measured cisplatin sensitivity
directly by means of cell viability tests after treatment. Take-
naka and colleagues reported that high protein expression level
of ERCC1 is signiﬁcantly correlated with low cisplatin chemo-
sensitivity (P= 0.04) using tumor biopsies collected from 41
NSCLC patients before treatment [18]. Wang and colleagues
used an ATP-based tumor chemosensitivity array (ATP-
TCA) to assess cell viability and found that increasing levels
of ERCC1 mRNA expression were correlated negatively with
cisplatin sensitivity in primary tumor cells collected from 20
NSCLC patients (P= 0.001) [19]. A similar study, using the
WHO tumor response guidelines and a combination
cisplatin/gemcitabine treatment, found that while there is a
signiﬁcant correlation between higher response rates and low
expression levels of ERCC1 mRNA in pretreatment primary
NSCLC tumor specimens, there was no signiﬁcant difference
in ERCC1 mRNA levels detected between responding and
non-responding tumors after the treatment [20]. The authors
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tion of post-treatment ERCC1 expression with overall
response is not contradictory to the above studies; rather,
the pretreatment levels of ERCC1 expression are a good indi-
cator for cisplatin chemosensitivity. This hypothesis was tested
in a phase III trial of 346 NSCLC patients, where treatment
was customized based on the pretreatment levels of ERCC1
mRNA expression in the patients. Speciﬁcally, patients with
high level ERCC1 expression were treated with docetaxel plus
gemcitabine, whereas patients with low ERCC1 expression
received docetaxel plus cisplatin. The signiﬁcantly higher
response rates were observed in the docetaxel plus cisplatin
group (P= 0.02) [21]. Other studies also corroborated the link
between ERCC1 expression levels and sensitivity to cisplatin in
NSCLC patients including a study of the link between ERCC1
expression levels in 761 NSCLC tumors and efﬁcacy (pro-
longed survival) of cisplatin-based adjuvant chemotherapy
(P= 0.009) [22] (Table 1).
However, ERCC1 is not a perfect biomarker for cisplatin
sensitivity, as a number of studies found a lack of correlation
between the two. Wachters and colleagues reported no signif-
icant correlation between ERCC1 expression levels and tumor
response in group of 33 stage III/IV NSCLC patients [46].
Similarly, Booton et al. found no signiﬁcant relationship
between ERCC1 mRNA expression and cisplatin sensitivity
in a group of 66 stage III/IV NSCLC patients [47]. One expla-
nation for the lack of signiﬁcant correlation is that these stud-
ies are based on patients treated with combination therapy
including cisplatin. The addition of other drugs, such as gem-
citabine or docetaxel, on tumor response can be a confounding
factor. Another study by Glaysher and colleagues used an
ATP-TCA to assess chemosensitivity in 49 surgically-resected
NSCLC tumor samples and ﬁt multiple-regression models to
explain sensitivity based on multiple gene expression proﬁles.
Their model did not ﬁnd ERCC1 expression to be a signiﬁcant
explanatory variable for cisplatin resistance compared to the
other genes present [48]. This result is surprising considering
the evidence above, but given the method that the models in
that study were constructed with, it is possible that some com-
bination of other predictive genes do better together than
ERCC1 expression does alone. A few other studies whichTable 1 Gene expression correlation with cisplatin sensitiv
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respectively; whereas M indicates that cisplatin sensitivity didfailed to ﬁnd a correlation between ERCC1 expression and
cisplatin sensitivity suffer from similar drawbacks (i.e., con-
founds from additional drugs other than cisplatin, models
not speciﬁc to ERCC1 expression, or inconsistency in ERCC1
expression quantiﬁcation methods used [49,50]) and do not
constitute sufﬁcient evidence to rebut those studies that do ﬁnd
a signiﬁcant link. Considering the large amount of evidence
cited above in contrast to the limited contradictory evidence,
we conclude that ERCC1 expression is a potentially reliable
biomarker for cisplatin sensitivity in NSCLC patients when
reliable detection techniques are available. This conclusion is
supported by a comprehensive and comparative review, which
considered many different factors (including the biomarkers
discussed in this review) and concluded that the strongest
evidence for increased resistance in NSCLC to platinating
agents is the expression of ERCC1 [51].
With this connection in mind, there have been many studies
attempting to link SNPs in ERCC1 with cisplatin sensitivity;
however, ﬁndings are often contradictory. SZ Wei et al.
performed a meta-analysis of 12 datasets from 556 NSCLC
patients consisting of genotypes and clinical outcomes to cis-
platin treatment and found a signiﬁcant correlation between
overall response rate (ORR) and the rs11615 polymorphism
(Table 2) [52]. Similarly, HB Wei et al. performed a meta-
analysis on 11 datasets and conﬁrmed the ﬁndings of SZ Wei
and colleagues [53]. However, Yu et al. performed a similar
meta-analysis of 1252 NSCLC patients and concluded there
was no signiﬁcant link between this polymorphism and
response to cisplatin treatment [54]. They claimed that their
study more accurately represented the underlying data and
that it had greater statistical power due to larger sample size.
Possible explanations for these discrepancies include con-
founders like race, age, smoker status. Clearly there is a need
for a more comprehensive study of ERCC1 polymorphisms
in relation to cisplatin response.XP family genes and cisplatin sensitivity in NSCLC
Also involved in the NER pathway is the family of XP genes
and their encoded proteins. Although it is well recognized thatity in NSCLC
Refs.
dy conducted in 761 patients [21,22]
g cancer cell lines [23–25]
dy conducted in 54 patients [26]
all cell lung cancer cell lines [27]
ouse cell lines [28,29]
dy conducted in 89 patients [30]
CLC cell lines [30,31]
dy conducted in 104 patients [32]
umor cell lines including NSCLC [33,34]
ografts [35]
umor samples and clinical study
pression and survival
[36–42]
lines and human breast cancer cell lines [43,44]
g cancer cell line [45]
to increased gene expression are indicated with › and ﬂ,
not change regardless of alterations in gene expression.
Table 2 Evidence for correlation of germline genetic variants with cisplatin sensitivity in NSCLC
Variant ID Host gene Eﬀect Evidence Refs.
rs11615 ERCC1 T/T genotype associated with low sensitivity Conﬂicting meta-analyses of clinical studies [52–54]
rs13181 XPD A/C and C/C genotypes associated with high
sensitivity in Caucasian populations and low
sensitivity in Asian populations
Meta-analysis of clinical studies [55]
rs7851395 CTR1 Associated with low sensitivity in Asian population Clinical study conducted in 282 patients [56]
rs12686377 CTR1 Associated with low sensitivity in Asian population Clinical study conducted in 282 patients [56]
rs1695 GSTP1 G allele associated with favorable response; A/G+
G/G genotypes more likely to be responders
Conﬂicting evidence: various clinical
studies and one meta-analysis
[3,57–61]
rs1138272 GSTP1 Ala/Val or Val/Val genotype associated with greater
median survival
Clinical studies [3,61]
GSTM1*0 GSTM1 Null genotype associated with increased sensitivity
compared to non-null
Meta-analysis of clinical studies [62]
rs560018 GSTM4 A/G genotype associated with decreased survival Clinical study in 973 lung cancer patients [63]
G/G genotype associated with decreased sensitivity 100 lymphoblastoid cell lines [63]
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evidence that expression levels of most XP- proteins are corre-
lated with sensitivity to cisplatin. Perhaps the best evidence is
in XPA. XPA is known to be involved in both DNA damage
detection in GG-NER and recruiting NER repair proteins
(e.g., ERCC1/XPF complex) to the site of damage. Wu and
colleagues found in two separate studies that by transfecting
a human lung cancer cell line with antisense XPA RNA,
mRNA levels of XPA are reduced and sensitivity to cisplatin
as measured by an MTT metabolic assay is increased [64,23].
Similarly, Zhang and colleagues showed that by silencing
XPA expression in a cisplatin-resistant NSCLC cell line, sensi-
tivity to cisplatin is increased [24]. Another study found that by
modulating HIF1a, a transcription factor known to bind to
the XPA promoter, XPA expression levels can be increased
or decreased, thereby decreasing or increasing cisplatin resis-
tance, respectively [25]. Finally, Rosenberg and colleagues
found that by transfecting a human lung cancer line with a
virus expressing a truncated version of the XPA protein, sensi-
tivity to cisplatin can be increased [65]. Although these ﬁndings
in cell lines warrant further investigation, the lack of clinical
evidence to date decreases the level of enthusiasm in using
the XP family proteins as markers for cisplatin sensitivity
(Table 1).
Certain SNPs in XP family genes have shown promise in cis-
platin sensitivity prediction. Speciﬁcally, rs13181 located in the
coding region for XPD has been intensively studied for its
effect on both lung cancer risk and cisplatin sensitivity. Qin
et al. performed a meta-analysis of 24 studies on platinum-
based chemotherapy for NSCLC patients and found that when
the analysis was stratiﬁed by race, the A/C and C/C genotypes
were signiﬁcantly associated with favorable objective response
in Caucasian populations, but among Asian populations they
found an association with the same polymorphisms and
decreased progression-free survival [55] (Table 2). SNPs in
other XP family genes have garnered some preliminary evi-
dence for their use as biomarkers of cisplatin sensitivity, but
comprehensive meta-analysis or large-cohort studies have not
been done in order to achieve sufﬁcient statistical power.
The lack of correspondence between mRNA/protein
expression studies and genetic variation studies along with
the multiple contradictory ﬁndings in sufﬁciently-powered
analyses indicates that the relationship between genotype and
response may not be a simple one-to-one function. A more
nuanced approach which looks at multiple SNPs within theNER pathway in conjunction has been shown to be a poten-
tially-powerful tool in predicting cisplatin sensitivity [57].
Copper transporters and cisplatin sensitivity
As discussed above, sensitivity to cisplatin is multifactorial and
the relative contribution of different pathways is still not well
elucidated. However, it has long been noted that cisplatin-
resistant cells tend to exhibit decreased intracellular drug
accumulation [66]. A recent study has established a signiﬁcant
correlation between intracellular platinum buildup and
reduction in tumor size [67]. It was previously thought that
the dominant mode for cisplatin’s entry into tumor cells was
through passive diffusion [66], but growing evidence has sup-
ported the role of copper transporters in the active inﬂux
and efﬂux of cisplatin [67].
Mechanism of action of copper transporters
Copper serves an important role in biological processes as a
cofactor for many enzymes. The intake of copper is thought
to be mediated by the protein human copper transporter 1
(hCTR1) encoded by the CTR1 (or SLC31A) gene [68]. The
copper is then chaperoned by ATX1, CCS and COX17 to
ATPase, copper transporting, alpha polypeptide A and B
(ATP7A and ATP7B), Copper-zinc superoxide dismutase
and cytochrome C oxidase, respectively [69]. Excessive intra-
cellular copper has been found to be regulated by two proteins,
ATP7A [70] and ATP7B [71]. While the role of this pathway
has been extensively studied with regard to copper transporta-
tion, only in the past decade and a half has attention been paid
to the role it might play in cisplatin transport and sensitivity.
Safaei and Howell [69] reviewed evidence based on cross-resis-
tance between copper and platinum drugs to demonstrate that
CTR1 and ATP7A/ATP7B play an important role in the active
regulation of intracellular Pt agents and corresponding
sensitivity. Kuo et al. additionally reviewed the structural-
functional and mechanistic aspects of these transporters [6].
CTR1/CTR2 and cisplatin sensitivity
The main body of work on the effects of copper transporters
on cisplatin sensitivity has been done mostly in cancers other
than NSCLC. However, it is becoming clear that these effects
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include evidence in cancers other than NSCLC, as one can
likely extrapolate between the various diseases. CTR1 was ﬁrst
shown to be related to cisplatin uptake and sensitivity in
strains of the yeast Saccharomyces cerevisiae in two studies.
CTR1 knockout yeast strains were shown to have a twofold
reduction in cisplatin uptake and cytotoxic effect of cisplatin
compared to wild-type CTR1 strains [28]. These results were
conﬁrmed in yeast and extended to mouse cell lines [29]. Con-
sidering the highly-conserved nature of the copper transport
pathway, these ﬁndings lead researchers to investigate the
effects of CTR1 in humans. Song et al. demonstrated that at
least one strain of a cisplatin-resistant small cell lung cancer
(SCLC) cell line exhibited reduced levels of CTR1 mRNA
compared to a cisplatin-sensitive cell line. They further showed
that CTR1-transfected SCLC cells had an increase in cisplatin
sensitivity [27]. Holzer et al. showed that in murine embryonic
ﬁbroblast cell lines, CTR1 deﬁciency was associated with
decreased accumulation of and increased resistance to cisplatin
[72]. Zisowsky et al. similarly showed that cisplatin-resistant
cervical and ovarian cancer cell lines exhibited reduced levels
of cisplatin accumulation and 1.51.8 fold reduction in
CTR1 mRNA expression [73]. These experimental results have
been reproduced in a number of subsequent studies [74–76].
Ishida et al. provided one of the ﬁrst studies of the clinical
importance of CTR1 mRNA expression. They found in two
separate studies involving 15 (P= 0.016) and 91 (P= 0.003)
patients that high expression of CTR1 mRNA was correlated
with increased disease-free survival in advanced ovarian cancer
when treated with platin-based therapy [77].
Chen et al. extended these results to NSCLC and found that
in pre-treatment samples from 54 advanced NSCLC patients
treated with cisplatin or carboplatin, high CTR1protein
expression level was a signiﬁcant prognostic factor for favor-
able chemotherapy response, progression-free survival
(P= 0.01) and overall survival (P= 0.047) [26]. In an intrigu-
ing pilot study, Fu et al. found that by pretreating patients
with a copper-lowering agent in order to re-sensitize plati-
num-resistant ovarian cancer tumors, four out of ﬁve patients
exhibited increased response to carboplatin. The proposed
method of action of this copper-lowering agent is that high
levels of copper cause a down-regulation of CTR1 and that
by removing some of the extracellular copper, CTR1 will be
up-regulated and allow for greater inﬂux of carboplatin into
tumor cells [78].
These results are promising in terms of using CTR1 as a
prognostic indicator for cisplatin sensitivity in NSCLC. How-
ever, more clinical evidence is needed before any conclusions
can be drawn. Ivy et al. recently suggested that although
CTR1 expression is correlated with platinum uptake, the major
entry pathway of platinum-based agents cannot be saturated
by excessive platinum [79]. Hall et al. reviewed effects of cellu-
lar accumulation of platinum-based drugs on sensitivity and
argued that the ability of CTR1 to transport platinating agents
is tissue-speciﬁc and that there is a possibility that the platinum
transported by CTR1 is not cytotoxic [80]. Overall, studies
about the impact of CTR1 on cisplatin sensitivity are largely
lacking in NSCLC. While we may be able to extrapolate from
studies in other cancers, their use is limited. Clearly more
studies are needed to elucidate the potential role of CTR1 as
a biomarker or target for treatment, but there is compelling
evidence that warrants larger and more powerful studies.CTR2 is located close to CTR1 on the human chromosome
arm 9q32; however, their respective mRNAs exhibit 0%
homology and their proteins share 33% protein identity [81].
Less intensively-studied than CTR1, CTR2 has recently been
shown to also have an impact on cisplatin sensitivity, albeit
in the opposite manner of CTR1. Blair et al. found that knock-
down of CTR2 increased uptake of cisplatin and cytotoxicity
in cell lines of mouse embryo ﬁbroblasts. They further found
a signiﬁcant correlation between CTR2 mRNA and protein
levels and cisplatin sensitivity in six ovarian cancer cell lines
[82]. Further studies in cancer cell lines [83] and some prelimin-
ary clinical studies (reviewed by Ohrvik et al.) [84] provided
some evidence for the role of CTR2 in cisplatin sensitivity.
However, to date there are no studies of CTR2 in NSCLC.
Therefore we cannot draw conclusions regarding the impact
of CTR2 on cisplatin sensitivity in NSCLC at the current time.ATP7A/ATP7B and cisplatin sensitivity
As mentioned above, both ATP7A and ATP7B are involved in
the efﬂux of copper from mammalian cells. In contrast to
CTR1, which is expressed in nearly every tissue in the body,
ATP7B is mainly expressed in the liver, kidney and brain,
while ATP7A is expressed in most tissues aside from the liver
[69]. Mutations in ATP7A and ATP7B are the causes of Men-
kes [70] and Wilson’s disease [71], respectively. Deﬁciency in
copper efﬂux is the main cause of excessive copper accumula-
tion in these two diseases, which leads to the hypothesis that
these efﬂux genes may be involved in the efﬂux of cisplatin
as well. Samimi and colleagues found that an increase in
ATP7A expression in post-treatment tumor samples is associ-
ated with poor survival in ovarian cancer patients
(P = 0.0057) [85]. In another study, they found that increased
expression of ATP7A is correlated with resistance to cisplatin
in ovarian cancer cell lines, but not with decreased accumula-
tion of intracellular platinum [86].
Similar results have been observed in NSCLC. Li et al.
found that a cisplatin-resistant NSCLC cell line that expressed
signiﬁcantly higher levels of ATP7A mRNA and protein than
the sensitive parental cell line can be partially re-sensitized by
silencing ATP7A with siRNA. They further found that the
presence of ATP7A in pretreatment tumor samples from 89
NSCLC patients was associated with worse response to cis-
platin-based chemotherapy, compared to patients negative
for ATP7A (P= 0.001) [30]. Recently Song et al. identiﬁed
miR-495, an miRNA that directly targets ATP7A. They found
that overexpression of miR-495 negatively regulates ATP7A
and can partially restore cisplatin sensitivity in a cisplatin-
resistant NSCLC cell line [31]. This ﬁnding provides an
intriguing possibility for a cisplatin-sensitivity biomarker, but
conclusive evidence is currently lacking.
ATP7B was ﬁrst proposed to be related to cisplatin sensitiv-
ity by Komatsu et al. when they found that human epidermoid
carcinoma cell lines transfected with ATP7B exhibited a 9-fold
increase in resistance to cisplatin and a decrease in cisplatin
accumulation [87]. Nakayama et al. found that the presence
of ATP7B mRNA and protein in samples collected from 104
ovarian cancer patients was a signiﬁcant prognostic factor
for poor response to cisplatin-based chemotherapy
(P= 0.048) [32]. In a broad study of 60 cancer cell lines,
Konkimalla et al. assessed the levels of 55 candidate
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They found that among 17 genes exhibiting signiﬁcant correla-
tion (including CTR1), ATP7B had the lowest P value at
0.0006 [33]. Inoue and colleagues were the ﬁrst to establish
the positive correlation between ATP7B mRNA levels and cis-
platin resistance in NSCLC tumor samples (P= 0.015) [34].
Recently the same correlation was demonstrated in vivo by cor-
relating ATP7B mRNA (P= 0.0389) and protein
(P= 0.0357) expression levels with cisplatin sensitivity in
NSCLC xenografts [35]. These ﬁndings are promising but do
not constitute sufﬁcient evidence to conclude that ATP7B is
a reliable biomarker for cisplatin sensitivity in NSCLC.
At the present time, research into potential germline
polymorphisms in copper transport genes as biomarkers for
cisplatin sensitivity is limited by the lack of potential candi-
date SNPs in those genes [88]. A recent meta-analysis of
pharmacogenomics examined the use of platinum-based ther-
apy for the treatment of NSCLC, no genes involved in the
copper transport pathway were examined [3]. There is one
study on the effects of SNPs in CTR1 on cisplatin sensitivity.
Xu et al. found that in 282 Chinese Han NSCLC patients
treated with platinum-based chemotherapy, two SNPs,
rs7851395 and rs12686377, in CTR1 were correlated with
both platinum resistance and overall survival (P< 0.05,
Table 2) [56]. No studies were reported that relate SNPs in
ATP7A/ATP7B to cisplatin sensitivity. However, in one
study involving 203 Japanese cancer patients, Fukushima-
Uesaka et al. identiﬁed 38 and 61 genetic variations in
ATP7A and ATP7B, respectively [89]. While this study does
not provide us with any insights into cisplatin treatment in
NSCLC, it provides researchers with some potential candi-
date SNPs to evaluate.
GST and cisplatin sensitivity
Finally, we review the role of GSTs, a class of phase II drug
metabolizing enzymes, in the efﬁcacy of cisplatin. GSTs are
involved in detoxiﬁcation of cisplatin and aid in the formation
of (inactive) platinum-glutathione conjugates, which can be
excreted or further metabolized due to their now-increased
solubility (see Figure 1) [58,88]. The rationale behind investi-
gating GSTs is that patients with null or deﬁcient GST
function may experience decreased platin detoxiﬁcation and
an increased sensitivity to cisplatin, possibly as a result of
increased active cisplatin concentrations. The focus in the liter-
ature has been primarily on GST pi 1 (GSTP1) because it is
expressed in different human epithelial tissues and is ‘‘the most
abundant GST isoform in the lung’’ [58,90,91]. GSTM genes
have also been widely investigated, in part due to their highly
polymorphic nature (see section below). Here we discuss the
expression and genetic polymorphisms of genes in the GSTP
and GSTM families and their associations with cisplatin
sensitivity.
GST mechanism of action
The mechanism of action of GSTs is relatively simple. Aquated
cisplatin can bind to DNA to form adducts; however aquated
cisplatin can also be inactivated via conjugation with
glutathione [88]. Glutathione is conjugated to substrates,
such as platinum, through the action of GSTs. Theseglutathione-platinum conjugates have increased solubility
and can be excreted by the ATP-binding cassette, subfamily
C (ABCC) transporter family [63,88].GSTP1 and cisplatin sensitivity
Previous research on GSTP1 focused on distinguishing human
lung cancer cell lines. In 1988, using Northern blot hybridiza-
tion analysis, Nakagawa et al. found that the levels of GSTP1
mRNA were signiﬁcantly higher in 3 NSCLC cell lines, com-
pared to SCLC cell lines [36]. Using a colony forming assay
to establish the IC50s for cisplatin for various cell lines, they
found that the IC50 of the SCLC were 36.67 times lower than
those for NSCLC cell lines. High sensitivity in SCLC cell lines
was correlated with low levels of GSTP1 mRNA expression
[36]. These results suggested that low levels of GSTP1 might
be responsible for higher cisplatin sensitivity. In 1997, Arai
et al. showed that patients with GSTP1-negative tumors had
signiﬁcantly better response than patients with GSTP1-positive
tumors [37]. Their study involved 60 patients (49 men and 11
women) who had previously untreated and unresected
NSCLC. These patients received cisplatin and etoposide and
tumor response was assessed when maximum tumor reduction
was clinically observed. 66.7% (16/24) of patients with
GSTP1-negative tumors were partially responsive, compared
to 25% (9/36) of patients with GSTP1-positive tumors. They
concluded that there is a signiﬁcant correlation between the
chemotherapy response and GSTP1 expression (characterized
by immunohistochemical staining and validated by RT-PCR)
(P= 0.0019) [37]. A similar study by the same group repli-
cated their initial ﬁndings: Patients with negative GSTP1
expression were more likely to be partial responders or have
a higher response rate than patients with positive GSTP1
expression (GSTP1-positive tumors) [38]. It is worth noting
that both studies had recruited more males than females,
whereas gender could be a potential confounding variable in
response.
To validate and further elucidate this relationship, Hida
et al. examined 11 NSCLC cell lines established from patients
who had not previously undergone treatment and observed
increased GSTP1 expression in cell lines with a higher IC50
for cisplatin-based chemotherapy [39]. However, this associa-
tion disappeared for cell lines derived from patients who had
previously received some combination chemotherapy (includ-
ing cisplatin-based chemotherapy). Furthermore, cell lines
established from patients before and after chemotherapy
showed no increase in the amount of GSTP1 protein. Cell lines
with acquired resistance to cisplatin also showed no increase in
the amount of GSTP1 protein. Taken together, these results
conﬁrm the observation of Arai and colleagues, but also imply
that GSTP1 may play a role in innate, but not acquired
resistance of tumors.
Hirano et al. analyzed GSTP1 levels from 126 surgically-
resected NSCLC tumors as well as in two normal and
cisplatin-resistant cultured lung cancer cell lines, H69 and
PC14 [40]. In the H69 cells, they observed an increase in
GSTP1 expression in the resistant strain compared to the par-
ent strain. In addition, they found GSTP1-negative patients
showed signiﬁcantly higher survival than GSTP1-positive
patients when treated with platinum-based adjuvant therapy
(P= 0.0219). This is only true in those NSCLC patients
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patients who received no treatment after resection, indicating
that GSTP1 expression is associated with survival only in
patients treated with cisplatin.
Similarly, Allen et al. found that higher GSTP1 nuclear
staining was signiﬁcantly associated with decreased survival
in stage I and II squamous cell carcinomas, a subtype of
NSCLC (n= 40, P= 0.02) [41]. Cytoplasmic staining showed
a similar trend, although it did not reach statistical signiﬁcance
(P= 0.15). This is not surprising since the proposed mecha-
nism of action for GSTs is in the nucleus. In contrast to Hir-
ano et al.’s work, they found no signiﬁcant correlation
between GSTP1 staining and survival for other histological
types of NSCLC. The discrepancy could be explained by the
failure of Hirano et al. to differentiate between histopatholo-
gical cell types in their analysis.
Rosell et al. analyzed expression of GSTP1 in mRNA iso-
lated from pretreatment biopsies of patients with metastatic
NSCLC [42]. In contrast to the previous studies, there were
no differences in response observed by treatment arms when
broken down by GSTP1 expression. The authors also found
that GSTP1 was not associated with time to progression or
survival. The lack of association could be explained by the
low GSTP1 expression in late stage metastatic lung cancer. It
would be consistent with Allen and colleagues’ ﬁndings that
GSTP1 expression is signiﬁcant only in stages I and II for
squamous cell carcinoma. Interestingly, it has been shown that
inhibition of nuclear transport of GSTP results in increased
sensitivity to cisplatin in colon, glioblastoma and lung
adenocarcinoma cell lines (a histopathological subtype of
NSCLC) [41].
These results are promising; however, based on low cis-
platin-glutathione conjugation rates, a recent study by Pek-
lak-Scott et al. concluded that cisplatin resistance attributed
to GSTP1 is not caused by cisplatin conjugation, but rather
modulation of other signaling pathways [92]. In a review of
glutathione-related enzymes, Tew suggests that the association
between GSTP1 expression and cisplatin sensitivity is likely a
by-product of pleiotropic stress as opposed to an active mech-
anism [93]. The precise nature of the relationship between
GSTP1 expression and cisplatin sensitivity is still unclear,
but their association has been observed consistently and may
serve as a useful biomarker.
Genetic polymorphisms in GSTP1 have been studied to
greater extent than its expression both for susceptibility to var-
ious cancers and for sensitivity to anticancer drugs. Here we
discuss two such polymorphisms: rs1695 and rs1138272
(Table 2). Among the studies reviewed below, there are dispa-
rate results. Some studies conﬁrmed a general trend for the
association of rs1695 with decreased cisplatin sensitivity, while
a number of other studies found that this SNP is associated
with favorable response and increased survival. Yet other stud-
ies found that the association is insigniﬁcant. There is evidence
that the rs1138272 is associated with prolonged survival.
Polymorphism rs1695 is a substitution of a wild type A
allele to a G allele, which results in an amino acid substitution
of a valine to an isoleucine. Such substitution affected the con-
jugate ability of GSTP1 to various substrates including plati-
nating agents [94,95] and decreased GSTP1 activity in a
gene/dose-dependent manner [94].
Sun et al. analyzed 113 Chinese Han patients that were
diagnosed with stage IIIA-IV histologically-conﬁrmed NSCLCand were on one of three platinum-based chemotherapies at 4
loci using a gel-based DNA microarray genotyping method
[58]. They conclude that the presence of rs1695 variant differed
signiﬁcantly between responders and non-responders. After
adjusted for various factors (gender, age at diagnosis, chemo-
therapy regimens), the odds ratio for response was 2.881
(P= 0.022) for those carrying at least one variant allele. In
other words, patients carrying the G variant allele at this locus
were more likely to be cisplatin responders. Similar observa-
tions were also reported in a recent study by Zhou and col-
leagues. They examined two SNPs including rs1695 using
blood samples from 111 stage IV Chinese NSCLC patients
treated with platinum-based therapy [59]. The authors found
that rs1695 variant allele was associated with favorable
response to platinum-based chemotherapy (adjusted
P= 0.0005). A meta-analysis of 24 publications performed
independently by 2 groups on 11 polymorphisms in 8 genes
found that rs1695 was signiﬁcantly associated with favorable
response to platinum-based chemotherapy, although the effect
was moderate and was only observed in Asian populations
(P= 0.0002) [3]. However, it is worth nothing that the
sub group that conﬁrmed this consisted only of two
publications [58,59].
However, other studies found opposite direction SNP
association. Wu et al. analyzed 13 SNPs in cisplatin-related
pathways, including rs1695, in 229 patients with stage IIIB
or IV NSCLC receiving ﬁrst-line cisplatin-based chemother-
apy. The variant allele of rs1695 was signiﬁcantly associated
with decreased survival (hazard ratio (HR) = 1.99,
P= 0.015); however, such association was not signiﬁcant after
adjusting for multiple comparisons [57]. Similarly, Booton
et al. analyzed 4 known polymorphisms, including rs1695
and rs1138272, in exons 5 and 6 of GSTP1 in 108 patients,
and found each addition of a *B allele, deﬁned by the authors
as having both one variant rs1695 and one variant 1138272
allele, resulted in a non-signiﬁcant inferior tumor response
and survival, quantiﬁed by a 22% increased risk of death, com-
pared to those who had wild type alleles of rs1695 and
rs1138272 [60]. Furthermore, patients with variant rs1138272
demonstrated greater median survival and a reduction in HR
of death of 0.56, which has not been addressed by other
authors. It is worth noting that one of the treatment arms
involves carboplatin and docetaxel (as opposed to cisplatin,
mitomycin and ifosfamide or cisplatin, mitomycin and vinblas-
tine); however, despite the use of carboplatin in one of the
treatment arms, they found no signiﬁcant difference between
treatment arms [60]. The lack of signiﬁcance of the *B allele
may be a result being underpowered. In combination with
the study by Wu and colleagues, these results warrant further
investigation of rs1695.
Lu et al. genotyped 424 and 425 stage III or IV NSCLC
patients treated with platinum-based chemotherapy for
GSTP1 genotypes in exon 5 and exon 6, respectively [61]. In
contrast to all aforementioned studies, they found that GSTP1
SNPs were not associated with survival. However, multivariate
analysis revealed a positive association between rs1138272
variant and prolonged survival compared to wild type with
an adjusted HR of 0.75. This effect was only observed for male
patients younger than 62. The authors stated that the lack of
follow-up clinical data and treatment information prevent
them from concluding that rs1138272 is correlated with cis-
platin response. Of note, the authors did not specify any drug
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were likely on some form of platinum-based chemotherapy
because it is the accepted standard of care. Given the lack of
information on treatment arms and newly-found association
with gender and age, it is unclear how useful this study is.
The discrepancy in these studies could be attributed by
small sample sizes (lack of power) as well as heterogeneity of
tumors, patients and treatments [88]. Alternatively, given sin-
gle polymorphisms have no signiﬁcant associations after
adjusting for multiple comparison, the effect of individual
polymorphisms may be simply minimal to modest [57]. Using
survival tree analysis and/or joint analysis of multiple variants,
Wu et al. suggest there is a signiﬁcant gene dosage effect and a
polygenic analytical approach should be used to predict clini-
cal outcomes.
Combining the above evidence, it seems that rs1695 is asso-
ciated with favorable response to cisplatin and may be useful
as a biomarker for predicting clinical outcomes on its own
or in combination with other biomarkers––i.e., as part of a
polygenic predictive analysis for patients. There are several
indications that variant rs1138272 may be associated with
greater median survival; however, conclusive data are lacking.
Both rs1695 and rs11138272 would beneﬁt from further anal-
ysis with larger sample sizes and homogenous populations in
terms of treatment regimen and histopathological tumor type
are needed to conclude what role they play in cisplatin
response in NSCLC patients.GSTM and cisplatin sensitivity
Similar to the GSTP family of genes, the GSTM genes encode
proteins involved in detoxiﬁcation of xenobiotics. Its function
with respect to NSCLC and cisplatin sensitivity is multifaceted
as it is potentially a determinant of both susceptibility to
NSCLC and response to cisplatin [96]. There are 5 genes in
GSTM family: GSTM1 through GSTM5. It is known that
different proteins in the GST Mu (GSTM) family bind specif-
ically to substrates such as the mutagen benzo[a]pyrene or the
anticancer alkylating agent bis-chloroethylnitrosourea
(BCNU) [96]. However, little has been done in studying the
effect of GSTM expression on cisplatin sensitivity.
The little evidence available generally indicates GSTM
expression does not have a signiﬁcant effect on cisplatin. For
example, three early studies found no link between GSTM
expression and cisplatin resistance. Saburi et al. found no
increase in GSTM expression in two cisplatin-resistant Chinese
hamster ovary cell lines compared to their parent cell lines [97].
Townsend et al. showed that a breast cancer cell line over-
expressing GSTM proteins exhibited no resistance to cisplatin,
among a number of other drugs [43]. Waxman and colleagues
monitored expression of different GST mRNAs in the livers of
adult male rats and observed no change in GSTM expression
in response to treatment with cisplatin [44]. However, a num-
ber of more recent studies have indicated that GSTM protein
expression may have a signiﬁcant association with cisplatin
sensitivity. Watson et al. showed that there is a signiﬁcant
down-regulation of the GSTM3 and GSTM4 genes (4.84 and
3.13-fold decrease) in a cisplatin-resistant breast cancer cell
line compared to the non-resistant parent cell line as measured
by expression microarray analysis and real-time RT-PCR [98].
The same group of investigators conﬁrmed these ﬁndings forGSTM3 using the same cell line and matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry [99].
In an intriguing meta-analysis of genome-wide association
studies, Wheeler et al. showed that in 608 lymphoblastoid cell
lines (LCLs) across seven panels that represent diverse world
populations, rs10431718, a SNP within an eQTL targeting
GSTM1, is signiﬁcantly associated with cisplatin IC50
(P= 0.017), indicating that the regulation of the expression
of GSTM1 has a signiﬁcant effect on cisplatin sensitivity
[100]. There also exists compelling evidence from rational drug
design studies of GSTM1’s importance in cisplatin sensitivity.
One such study by Wang and colleagues found that by using a
novel GST inhibitor which acts on GSTM1, sensitivity to cis-
platin in a lung cancer cell line increased with a 2.7-fold
decrease in IC50. They further conﬁrmed their ﬁndings by
depleting those cells of GSTM1 with a speciﬁc siRNA and
observed a 1.4-fold decrease in cisplatin IC50 [45]. While some
of the recent evidence is promising, it is still largely indirect
and contradicts earlier direct studies. Therefore, more evidence
is needed to elucidate the role of GSTM expression in cisplatin
sensitivity.
Genes in the GSTM family are highly polymorphic. Four
functional alleles have been observed in GSTM1, including
GSTM1*A, GSTM1*B, GSTM1*0 and GSTM1*1 · 2. The
ﬁrst two correspond to catalytically-identical proteins (incor-
porating lysine and asparagine, respectively), while the latter
two correspond to a deleted allele and a duplicated gene,
respectively [101]. No known genetic polymorphisms had been
reported for GSTM2 and GSTM5 yet, whereas GSTM3 and
GSTM4 each have two distinct alleles (GSTM3*A and
GSTM3*B; and GSTM4*A and GSTM4*B, respectively)
[101]. The highly polymorphic nature has made GSTM genes
the target of many studies. However, many of those studies
have been focused on the relationship between GSTM geno-
type and susceptibility to cancer [101]. It is likely that GSTM
genes play a role both in cancer susceptibility, by detoxifying
potential carcinogen, and in drug sensitivity, by deactivating
anticancer compounds.
The null genotype of GSTM1 has been of particular interest
as it occurs in roughly half of the human population with large
variation across ethnic populations [102]. A meta-analysis of
90 studies from 1990 to 2009 of associations between 170
genetic polymorphisms and lung cancer outcome found that
GSTM1*0, the null genotype, was signiﬁcantly associated with
worse overall survival [103]. However, this conclusion was
based on only two studies [104,105]. In particular, only one
study had the majority of their patient population treated with
cisplatin (70 out of 81 total patients), and the cisplatin treat-
ment was in conjunction with etoposide. Furthermore, this
study included 20 SCLC patients, which makes extrapolation
to NSCLC patients difﬁcult. More recent evidence has come
to light, which indicates that the GSTM1 null genotype is asso-
ciated with improved response to platinum-based therapy [62].
Yang and Xian conducted a meta-analysis incorporating 455
NSCLC patients treated with platinum-based therapy with a
known GSTM1 genotype. They found that compared to the
non-null genotype, the null genotype is signiﬁcantly associated
with good response (odds ratio = 1.77, 95% CI = 1.192.62).
Nonetheless, it is worth noting that this association holds in
East-Asian patients, but not among Caucasian patients [62].
Other GSTM polymorphisms have been less intensively
studied vis-a`-vis cisplatin sensitivity. Moyer et al. provided
206 Genomics Proteomics Bioinformatics 12 (2014) 198–209one such study. They genotyped samples from 973 lung
cancer patients (17% as SCLC) for SNPs from glutathione
pathway related genes and found that rs560018, located on
GSTM4, is signiﬁcantly associated with improved survival
(P= 0.002). They further found that in 100 LCLs treated with
cisplatin, the same SNP is associated with cisplatin IC50
(P= 0.019) [63].
Evidence for both expression and genetic polymorphisms in
the GSTM family associated with cisplatin sensitivity is
currently lacking, but further investigation is warranted,
especially with regard to the GSTM1 null genotype.Conclusion
In summary, we have discussed three representative pathways
related to cisplatin sensitivity in NSCLC. Within the NER
pathway, ERCC1 expression appears to be a promising candi-
date for a cisplatin sensitivity biomarker. While expression of
other genes may be similarly predictive of cisplatin sensitivity,
current evidence is inconclusive. Within the copper transport
pathway, there is varying degrees of evidence available for
CTR1, ATP7A and ATP7B to support their use as biomarkers,
but are a promising set of genes to consider. Current evidence
is conﬂicting on the potential use of GST-related biomarkers.
Looking ahead, we would propose larger and more powerful
studies on the use of ERCC1 as a cisplatin sensitivity
biomarker as it is currently the most promising lead.Competing interests
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